Introduction
Epilepsy affects approximately 40,000 people in Scotland. Each year approximately 100 people from this population will die from an epilepsy-related death.
1 Sudden unexpected death is defined as the: ''Sudden, unexpected, witnessed or unwitnessed, nontraumatic and nondrowning death in patients with epilepsy, with or without evidence for a seizure and excluding documented status epilepticus, in which postmortem examination does not reveal a toxicologic or anatomic cause for death.'' 2 Post-mortem studies indicate that up to 60% of all epilepsy-related deaths can be accounted for by SUDEP, 3 making it the single most common cause of mortality in epilepsy. The Scottish Intercollegiate Guidelines Network (SIGN) state that the provision of information on SUDEP is 'essential' to newly diagnosed patients. 4 Further to this, a fatal accident inquiry (FAI) in 2002 into a SUDEP-related death concluded that: ''..in the vast majority of cases there should be a discussion'' regarding SUDEP with patients. A further FAI in 2011 into two SUDEP-related deaths concluded that: ''The vast majority of patients with epilepsy. . . should be advised of the risk of SUDEP'' unless defined exclusion criteria are met. 5 These conclusions, although not legally binding, reflect available guidelines and advocacy groups are in support of these recommendations.
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There has, however, been discrepancy between these guidelines and practice, with the National Sentinel Clinical Audit of Epilepsy related Deaths finding that only 1% of those who died from SUDEP in England and Wales had documented evidence of SUDEP discussion in their secondary care notes. 3 Further to this Morton et al. found that only 5% of British Neurologists would inform all patients of SUDEP, 7 with similar findings from other European countries. 8 With this discrepancy between guidelines and practice and the limitations of previous studies due to selection bias 3 and self reported practice 7, 8 we aimed to design and carry out an audit which gives some insight into current clinical practice in a large tertiary centre.
Methods
All patients who attended a specialist epilepsy clinic (inclusive of all consultant, trainee and nurse-led appointments) between 1st January 2009 and 30th June 2009 in Tayside were entered into the Results: Overall, a documented SUDEP discussion was noted in 14/345 (4%) cases. Patients were statistically more likely to have a documented SUDEP discussion if they had ongoing generalised tonicclonic seizures, with a trend also towards informing those non-compliant with medication. Conclusion: Patients were more likely to be informed of SUDEP if they had potentially modifiable risk factors identified. There was, however, no documented evidence to suggest that SUDEP is being discussed in the majority of cases.
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study. An electronic clinic letter search was then performed to identify all patients who had had at least 2 unprovoked seizures, thereby fulfilling the diagnostic criteria for epilepsy. A 5 year retrospective case note analysis was then performed to: (1) determine if there was documented evidence of SUDEP discussion and (2) identify risk factors for SUDEP in each case. 9, 10 Descriptive statistics were used for risk factors and Fisher's 2-tailed test was used for comparison between risk factor groups.
Results

Basic demographics
Six hundred and two patients were seen in clinic; 367 fulfilled the criteria for epilepsy (new referrals = 97; reviews = 270). Three hundred and forty five case notes were available for review. The mean age at review was 41.4 years and 175 (50.7%) were male.
Clinical characteristics
Forty-nine percent of patients had cryptogenic epilepsy, 16% idiopathic epilepsy, 13% symptomatic and 21% had another type. The predominant seizure type in the majority of cases was generalised tonic-clonic seizures (43%), 35% had complex partial seizures, 15% simple partial seizures, and 8% had another predominant type, including myoclonic and absence seizures.
Documented SUDEP discussion
In 14 patients (4%) a documented discussion of SUDEP in the last 5 years was recorded; a subgroup analysis of risk factors identified in this group is shown in Fig. 1 . Cross tabulation of the probability of SUDEP discussion occurring in all those with identified risk factors for SUDEP is demonstrated in Table 1 .
Discussion
There is little evidence from this single tertiary centre study that the risk of SUDEP is being discussed with the vast majority of patients. Our current practice is consistent with previous studies but is at odds with the recommendations of both SIGN 4 and NICE.
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Despite the small numbers informed of SUDEP two factors significantly influenced the likelihood of SUDEP discussion occurring: those with ongoing generalised seizures were more likely to be informed and those with drug resistant seizures were less likely to be informed. Further to this there was also a trend towards discussing SUDEP with those non-compliant with medication. This suggests that patients are more likely to be told if they have potentially modifiable risk factors for SUDEP identified. This association has not been previously reported.
There are a number of factors which may underestimate the true number of informed patients. It may be speculated that the risk was discussed but not documented and similarly that discussion was documented in contemporaneous handwritten clinic notes but not in their audited clinic letter. It may also be that chronic patients had been informed greater than 5 years ago or that that patients may have received written information regarding SUDEP from another source. It is impossible to predict the number of patients in whom SUDEP was discussed but where the discussion was not documented. The majority had both handwritten entries and electronic clinic letters reviewed, however in some only clinic letters were available. There were no instances when discussion of SUDEP was documented in one source but not the other. There is no consensus on how often patients should be informed, although 5 years was considered 'good practice'. Whilst it was not routine practice over the period of audit to distribute written information on SUDEP, some of the patients attending the epilepsy specialist nurse for the 1st time may have been provided with such information which was not documented; the total number of patients with such contact was 34.
Another important issue is what information a clinician must provide before it is considered the patient is fully informed. It may be argued that 'serious harm' could be a surrogate term for death and therefore this may have been discussed in preference of SUDEP. In an additional 13 patients the term serious harm was documented in the medical records. If these factors are taken into consideration, assuming that 'serious harm' is an acceptable alternative term to SUDEP, and that all those who met the epilepsy specialist nurse were given written information, the total informed would only increase from 4% to 17% of our clinic population.
In general the audit is a reasonably robust reflection of local clinical practice. It is unclear whether the data is generalisable to the UK as a whole but is consistent with previous self reported practice by members of the ABN. It is unlikely that our data was subject to selection bias as the majority of patients would be reviewed during a 6-month period and 94% of all case notes were available for review. A further cycle of the audit loop is planned and it will be interesting to determine whether clinical practice has changed in the light of the recent FAI.
Overall the low number of patients in whom SUDEP was discussed is perhaps not surprising given the results from previous publications. Much debate has been generated about the discussion of SUDEP with patients. Advocacy groups and guidelines, generated from medical opinion, are clear that all should be told, however concern has been raised from the medical community that a 'one-size fits all' approach is not appropriate for SUDEP Fig. 1 . SUDEP informed group: risk factors (n = 14). discussion due to the risk heterogeneity. It has been argued that informing those with drug resistant epilepsy with a high but nonmodifiable risk of SUDEP will undermine a patient's 'right not to know' and cause unnecessary distress. Conversely, academic debate has failed to reach a conclusion as to whether it is ethically right to inform all or only those with risk factors for SUDEP. 12 Without evidence that informing patients will lower SUDEP incidence, or that discussion could cause harm to patients, these theories remain speculative. It is then less surprising still that with these unresolved issues that the majority of our patients were not being informed of SUDEP.
In the absence of overwhelming evidence to suggest that clinical practice changes outcomes, clinicians are likely to consider the risk of SUDEP and balance this with the perceived risk of causing unnecessary anxiety on a case to case basis. The remit of this study was simply to evaluate actual clinic practice and further studies are required to explore further why SUDEP is currently being discussed in only the minority of patients. An honest and frank debate is required between clinicians, patient advocacy groups and those involved in developing guidelines to allow one to reconcile the disparity between guidelines and clinical practice with regard to SUDEP.
